Roth Capital Starts CymaBay Therapeutic (CBAY) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Stifel Nicolaus Starts CymaBay Therapeutic (CBAY) at Buy
September 17, 2014 6:40 AM EDTStifel Nicolaus initiated coverage on CymaBay Therapeutic (NASDAQ: CBAY) with a Buy rating and a price target of $10.00.
For an analyst ratings summary and ratings history on CymaBay Therapeutic click here. For more ratings news on CymaBay Therapeutic click here.
Shares of CymaBay Therapeutic closed at $7.37 yesterday.
... More


